- Probiotics were discussed as useful only for post-antibiotic or post-flare microbiome reconstruction, not for preventing or managing active flares; their role is to “reconstruct the microbiome after it’s been nuked from orbit.”  
- A request for black-market or low-cost personalized cancer immunotherapy (after mainstream pembrolizumab failed) prompted suggestions to contact Andrew Hessel and explore Human Genome Inc. resources, CAR-T cell therapy, and early-access NHS schemes.  
- AOH1996, a small-molecule PCNA inhibitor, was highlighted as entering Phase I human trials after showing efficacy against ~50 cancer cell lines; participants debated its promise versus DIY risks.  
- Thomas Seyfried’s 6-diazo-5-oxo-L-norleucine (DON) “press-pulse” metabolic therapy was introduced as a concept for glutamine-addicted tumors, though participants cautioned that it requires professional crash-team support and is not a garage-lab project.  
- The group emphasized that terminal patients should burn money on experienced medical teams rather than solo experimentation, noting that cytokine storms and other lethal complications make DIY cancer biohacking extremely dangerous.  
- ClinicalTrials.gov was recommended for locating worldwide immunotherapy trials, but a Russian patient discovered no accessible trials due to geopolitical restrictions, illustrating barriers faced outside the US/EU axis.